SuperworthChampions Oncology profit margin CSBR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −1.8%
- Operating margin, 12 months
- −1.7%
- Net margin on a year earlier
- −7.0 pts
- Peer median
- 6.8%
Over the twelve months to Jul 31, 2026, Champions Oncology kept −1.8% of its revenue as net profit, with an operating margin of −1.7% and a gross margin of 49.8%.
Five years earlier its net margin was 0.3%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −1.9% | −1.9% | 48.0% |
| FY2025 | 8.3% | 8.0% | 50.1% |
| FY2024 | −14.5% | −14.7% | 41.4% |
| FY2023 | −9.9% | −9.8% | 45.2% |
| FY2022 | 1.1% | 1.2% | 51.9% |
| FY2021 | 0.9% | 0.9% | 47.7% |
| FY2020 | −6.1% | −5.6% | 47.1% |
| FY2019 | 0.5% | 1.0% | n/a |
| FY2018 | −7.3% | −6.7% | n/a |
| FY2017 | −44.7% | −44.2% | n/a |
| FY2016 | −93.4% | −92.2% | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | −64.0% | −54.1% | n/a |
| FY2013 | −76.1% | −74.7% | n/a |
| FY2012 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | −1.8% | −7.0 pts | −1.7% | |
| Q4 FY26 | −1.9% | −10.2 pts | −1.9% | |
| Q3 FY26 | −4.0% | −15.0 pts | −4.5% | |
| Q2 FY26 | 4.2% | +5.3 pts | 3.7% | |
| Q1 FY26 | 5.1% | +11.7 pts | 4.7% | |
| Q4 FY25 | 8.3% | +22.8 pts | 8.0% | |
| Q3 FY25 | 11.0% | +30.7 pts | 10.7% | |
| Q2 FY25 | −1.1% | +18.2 pts | −1.5% | |
| Q1 FY25 | −6.6% | +7.8 pts | −6.7% | |
| Q4 FY24 | −14.5% | −4.6 pts | −14.7% | |
| Q3 FY24 | −19.8% | −14.0 pts | −19.5% | |
| Q2 FY24 | −19.3% | −19.5 pts | −19.0% |
Against its peers
Companies in Healthcare nearest Champions Oncology's size, closest first, today.
| Company | Profit margin |
|---|---|
| CSBRChampions Oncology | −1.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| APTAlpha Pro Tech | 6.8% |
| ATNMActinium Pharmaceuticals | n/m |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| NEPHNephros | 8.4% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
Where Champions Oncology ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Champions Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.